Form 4: Boston Scientific EVP John Bradley Sorenson Reports Stock Transactions

Executive Vice President of Global Operations at Boston Scientific, John Bradley Sorenson, reports acquisition and disposal of company stock, including transactions related to performance share units and sales under a pre-established trading plan.

Summary

• John Bradley Sorenson, EVP at Boston Scientific, reported several transactions involving Boston Scientific common stock.
• On February 11, 2025, Sorenson acquired 10,182 shares related to performance share units at $0.00, and disposed of 3,793 shares at $105.98.
• On February 12, 2025, Sorenson disposed of 2,156 shares at $0.00 and sold 6,389 shares at a weighted average price of $105.0633.
• Following these transactions, Sorenson directly owns 24,293 shares of Boston Scientific common stock.
• The sale of shares on February 12, 2025, was executed under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
• The performance share units were awarded on February 16, 2022, based on the company's total shareholder return performance relative to the S&P 500 Health Care Index over a three-year period ending December 31, 2024, and subject to a three-year individual service period.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports stock transactions, including the vesting of performance share units and sales under a pre-established plan. There are no explicit positive or negative indicators, but the vesting of performance share units suggests the company met certain performance targets.

Positives

• The vesting of performance share units indicates that the company met certain performance criteria related to total shareholder return relative to the S&P 500 Health Care Index.

Negatives

• The sale of shares by an executive could be interpreted negatively by some investors, although it was conducted under a pre-established 10b5-1 trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create uncertainty in the market.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's performance and future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards, such as the performance share units granted to John Bradley Sorenson.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in a transparent and compliant manner.
• Comparing Sorenson's transactions to those of executives at similar medical device companies like Medtronic or Abbott could provide a broader context for assessing the significance of these transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, potentially influencing short-term stock price fluctuations.
• The vesting of performance share units could positively impact employee morale, as it reflects the achievement of company performance goals.

Key Dates